Equazen® Pro Softgels

Description

EQUAZEN® PRO SOFTGELS  

MEDICAL FOOD  

Product Overview   

EQUAZEN® PRO is a specialized medical food designed to sharpen your focus, improve inattentive behavior, social interactions, and support a balanced mood.^† 

 In *19 clinical studies including 6 ADHD clinical trials, children and teens using EQUAZEN® PRO saw significant improvements in their focus, attention, academic performance, and mood stability. 

Benefits

• Supports children’s attention control, vocabulary development, and immediate memory recall ^†
• Reduces inattentive behavior^† 
• Enhances academic performance^†
• Supports a balanced mood^†
• Offers safe and effective nutritional support, suitable for use alone or with common prescription ADHD medications^† 

Who Can Benefit 

 Individuals with ADHD or those experiencing symptoms like difficulty focusing, lack of productivity, and impulsivity who are seeking additional nutritional support. 

 Key Features

• Clinically Proven Formula: Includes a clinically proven balance of omega-3 and omega-6 fatty acids, featuring GLA, making it an ideal choice for managing ADHD symptoms.^† 
• Sustainable Sourcing: Our suppliers are certified by Friend of the Sea® for their commitment to responsible and sustainable sourcing.
• Quality: We use innovative patented purification processes to reduce contaminants, oxidative impurities, environmental pollutants, and toxins, improving the clarity, quality, taste, and smell of our product.
• Eco-Friendly Production: Our fish oil production uses technologies powered entirely by renewable energy.We use innovative patented purification processes to reduce contaminants, oxidative impurities, environmental pollutants, and toxins, improving the clarity, quality, taste, and smell of our products.

Suggested Use

Suitable for ages 5 and up: Take 3 softgels daily with food or as directed by a healthcare professional.

Storage 

 Store at room temperature (59°-85°F). 

Detailed Overview  

EQUAZEN® PRO is a specialized medical food designed specifically for individuals with ADHD and related conditions, where fatty acid deficiencies cannot be corrected by diet alone. 

EQUAZEN® PRO has been well-established in Europe since 1999 and made its debut in the U.S. market as a medical food in 2020. 

EQUAZEN® PRO is the only ADHD-specific medical food with a clinically proven ratio of omega-3 and omega-6 fatty acids, including GLA.^† 

Traditional fish oil products typically contain only omega-3 fatty acids. A 2022 review published in Nutrients concluded that omega-3 fatty acids alone might not be sufficient to effectively support patients with ADHD and neurodiverse conditions.¹ 

 Overall, studies show a combination of EPA and DHA with GLA in a 9:3:1 ratio is linked to improvements in ADHD symptoms. This suggests that a combination of PUFAs may lead to better outcomes.¹ 

EQUAZEN® PRO features a unique ratio of omega-3 and omega-6 fatty acids — 9:3:1 EPA:DHA — that supports healthy fatty acid metabolism and balanced omega fatty acid levels, providing additional support for individuals with ADHD to reach their full potential.*^† 

Omega-3 & 6 Oils	1700 mg
Omega-3 Fatty Acids	732 mg
As EPA	558 mg
As DHA	174 mg
Omega-6 Fatty Acids
As GLA	60 mg

^†EQUAZEN® PRO is a medical food to address fatty acid deficiencies common in people with ADHD and some related neurodiverse conditions that cannot be resolved by normal diet modification alone. In clinical trials* among kids and teens with ADHD, the EQUAZEN® PRO formula showed on average significant improvements in focus, attention, academic performance, and balanced mood. USE UNDER MEDICAL SUPERVISION. *19 clinical studies include 6 ADHD clinical trials. 

 References 

1.  D’Helft J, Caccialanza R, Derbyshire E, Maes M. Relevance of ω-6 GLA Added to ω-3 PUFAs Supplements for ADHD: A Narrative Review. Nutrients. 2022;14(16):3273. Published 2022 Aug 10. doi:10.3390/nu14163273 

2.  Barragán E, Breuer D, Döpfner M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children With ADHD. J Atten Disord. 2017;21(5):433-441. doi:10.1177/1087054713518239 

3. Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014;3(2):101-108. doi:10.1002/cpdd.84